A carregar...
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable safety profile with promising efficacy in phase 1 studies in patients with primary and secondary myelofibrosis (MF). This multicenter phase 2...
Na minha lista:
Publicado no: | Blood |
---|---|
Main Authors: | , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society of Hematology
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490373/ https://ncbi.nlm.nih.gov/pubmed/25762180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-484832 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Internet
https://ncbi.nlm.nih.gov/pmc/articles/PMC4490373/https://ncbi.nlm.nih.gov/pubmed/25762180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-484832
Cannot write session to /tmp/vufind_sessions/sess_91c1u3feld8d8kg35ivteuvul4